stella
beta
LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy. — Stella
Recruiting
Back to Prostate Cancer (Adenocarcinoma) trials
Trial locations
(1 site)
Belgium
Institut Jules Bordet, Brussels
View full record on ClinicalTrials.gov